CF
CTNM

Corebridge Financial’s Contineum Therapeutics CTNM Stock Holding History

Corebridge Financial’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5,139
Closed -$35.9K – 2914
2025
Q1 		$35.9K Sell
5,139
-76
-1% -$691 ﹤0.01% 2806
2024
Q4 		$76.4K Buy
5,215
+2,202
+73% +$34.9K ﹤0.01% 2680
2024
Q3 		$57.7K Sell
3,013
-722
-19% -$13.8K ﹤0.01% 2836
2024
Q2 		$65.8K Buy
+3,735
New +$60.2K ﹤0.01% 2805

Other funds holding CTNM

JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Corebridge Financial's CTNM Position: Q2 2025 in Review

Corebridge Financial sold out of Contineum Therapeutics (CTNM) in Q2 2025, closing a stake of 5,139 shares — an estimated $35.9K sold.

Corebridge Financial first reported a position in CTNM in Q2 2024 and held it in 4 quarters. The position peaked at $76.4K in Q4 2024. 70 funds tracked by Wall St. Rank hold CTNM as of Q2 2025.

  • Corebridge Financial reported no remaining Contineum Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 5,139 Contineum Therapeutics shares in Q2 2025, an estimated $35.9K.
  • Corebridge Financial first reported a position in Contineum Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Contineum Therapeutics position peaked at $76.4K in Q4 2024.
  • 70 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.